SFDA accelerated approval oncology: ANKTIVA's breakthrough in NSCLC treatment

Key Takeaways

• First-in-world approval: The SFDA is the first regulator globally to authorize ANKTIVA for metastatic NSCLC, positioning Saudi Arabia as an early-access market for this IL-15 superagonist.
• Checkpoint-experienced population: The approval covers adults whose disease progressed after standard-of-care therapy, including prior immune checkpoint inhibitors, based on data from the single-arm QUILT-3.055 study.
• Immune restoration: ANKTIVA activates natural killer (NK) cells, CD8+ T cells, and memory T cells without stimulating regulatory T cells, potentially reversing immune evasion in refractory NSCLC.
• Confirmatory phase 3 underway: The ResQ201A trial (NCT06745908) is evaluating ANKTIVA plus tislelizumab and docetaxel versus docetaxel monotherapy in ICI-resistant NSCLC to verify long-term clinical benefit.
• Prior FDA precedent: The U.S. FDA approved ANKTIVA for BCG-unresponsive NMIBC in April 2024, validating the IL-15 superagonist platform in oncology.

What Did the SFDA Approve?

The SFDA granted conditional approval to ANKTIVA in combination with an immune checkpoint inhibitor for adult patients with metastatic NSCLC whose disease progressed after standard-of-care therapy. ImmunityBio announced the approval on January 14, 2026, noting that the SFDA is the first regulator worldwide to clear the drug for this indication. The approval is conditional on the completion of confirmatory trials that demonstrate sustained clinical benefit.

Under the SFDA pathway, the manufacturer must conduct post-approval studies to verify the survival signal seen in earlier trials. If those studies fail, the regulator can withdraw the authorization. This approach balances urgent patient access with long-term evidence requirements.

How Does ANKTIVA Restore Anti-Tumor Immunity?

ANKTIVA is an IL-15 receptor agonist that binds to the IL-15 receptor complex on immune cells. This triggers growth and activation of NK cells, CD4+ helper T cells, CD8+ killer T cells, and memory T cells. The drug does not stimulate regulatory T cells (Tregs), which suppress anti-tumor responses. The result is a broad restoration of innate and adaptive immunity.

For NSCLC, patients get ANKTIVA by subcutaneous injection with a checkpoint inhibitor. The checkpoint drug removes inhibitory signals on T cells, while ANKTIVA expands and activates those same cells. This dual approach aims to overcome resistance that develops after prior immune therapy.

What Clinical Evidence Supported the Decision?

The SFDA reviewed data from two ImmunityBio studies to reach its decision. The primary evidence came from QUILT-3.055 (NCT03228667), a phase 2b single-arm trial in patients with advanced solid tumors who had previously received PD-1/PD-L1 checkpoint inhibitors. In the NSCLC cohorts, investigators observed an association between increased absolute lymphocyte count (ALC) and improved overall survival.

Data cited in the ResQ201A phase 3 design show median overall survival in QUILT-3.055 was 14.3 months overall. Patients who maintained ALC ≥ 1.2 x 10³/μL lived a median of 21.1 months. Standard docetaxel alone in second-line NSCLC yields a median overall survival of about 9 months. The SFDA found this potential survival gain worthy of conditional approval.

The agency also considered biological activity data from QUILT-2.023, a randomized trial in first-line NSCLC that showed ANKTIVA restores and maintains lymphocyte counts. Together, the two trials provided a mechanistic and clinical rationale for the accelerated pathway.

How Does This Compare With Global Approvals?

ANKTIVA's approval footprint varies by region and indication. The table below summarizes the current regulatory status for the drug's two lead indications.

ANKTIVA Regulatory Status by Market

Market	Regulator	Indication	Approval Type	Date
Saudi Arabia	SFDA	mNSCLC after SOC + checkpoint inhibitor	Accelerated conditional	Jan 2026
United States	FDA	BCG-unresponsive NMIBC with CIS	Full (breakthrough)	April 22, 2024
European Union	EC	BCG-unresponsive NMIBC with CIS	Conditional MA	Feb 2026
United Kingdom	MHRA	BCG-unresponsive NMIBC with CIS	Approved	July 2025

The U.S. FDA approved ANKTIVA for NMIBC on April 22, 2024, based on QUILT-3.032 (NCT03022825). In that single-arm study of 77 patients, the complete response rate was 62% (95% CI: 51, 73). Fifty-eight percent of responders kept their complete response for at least 12 months, and 40% for at least 24 months. The European Commission followed with a conditional marketing authorization for NMIBC in February 2026. The UK's MHRA granted approval in July 2025. Neither the FDA, EMA, nor MHRA has yet approved ANKTIVA for NSCLC. That makes the SFDA decision a global first in oncology.

Who Is Eligible for Treatment?

The SFDA approved ANKTIVA for adults with confirmed metastatic NSCLC (stage IV disease) whose cancer progressed on or after prior standard-of-care therapy. This population includes patients who received prior chemotherapy and/or checkpoint inhibitor-based immunotherapy. Patients must have documented disease progression to qualify. Specific performance status and organ function requirements will be defined in the product labeling and local treatment guidelines.

What Are the Expected Side Effects?

The SFDA disclosed safety data from both the lung and bladder cancer programs. In NSCLC trials, the most common adverse events were injection-site reactions (redness, pain, or itching), chills, fatigue, fever, nausea, influenza-like symptoms, and loss of appetite. In the NMIBC program, common adverse events included elevated creatinine, dysuria, hematuria, urinary frequency, urinary urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills, and pyrexia.

Doctors should watch for immune-related events and cytokine-release symptoms, especially during the first doses. Subcutaneous delivery may be easier to tolerate than IV therapy. That supports outpatient care.

What Are the Next Steps in Development?

The ResQ201A phase 3 trial (NCT06745908) will confirm ANKTIVA's survival benefit in NSCLC. The study randomizes 462 patients 2:1 to ANKTIVA plus tislelizumab and docetaxel versus docetaxel alone. Patients must have stage IV NSCLC that resisted a single line of checkpoint inhibitor therapy, with or without chemotherapy. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, objective response rate, and duration of response. The trial is already enrolling patients.

Beyond NSCLC, ImmunityBio is testing ANKTIVA with CAR-NK cell therapy and other agents in more tumor types. The company also plans to open a regional office in Saudi Arabia. It will partner with BioPharma Cigalah for sales across the Middle East and North Africa.

Frequently Asked Questions

Primary Sources

1. Saudi Food and Drug Authority. SFDA Approves Registration of "Anktiva" for the Treatment of Bladder and Lung Cancer. Official SFDA announcement.
2. ImmunityBio, Inc. Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA in Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. Press release, January 14, 2026.
3. U.S. Food and Drug Administration. FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. April 22, 2024.
4. ClinicalTrials.gov. QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667).
5. ClinicalTrials.gov. QUILT-3.032: BCG in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer (NCT03022825).
6. Journal of Clinical Oncology. Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy. ASCO 2026 Annual Meeting, Abstract TPS8671.